Humacyte Inc reports results for the quarter ended June 30 - Earnings Summary

• Humacyte Inc HUMA.OQ reported a quarterly adjusted loss of 24 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -48 cents. The mean expectation of six analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -20 cents to -14 cents per share.

• Revenue was $301.00 thousand​; analysts expected $1.00 million.

• Humacyte Inc's reported EPS for the quarter was a loss of 24 cents​.

• The company reported a quarterly loss of $37.66 million.

• Humacyte Inc shares had risen by 18.7% this quarter and lost 50.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 8.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Humacyte Inc is $6.50, about 61.8% above its last closing price of $2.48

This summary was machine generated from LSEG data August 11 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)